Showing results (241-250 of 259) with videos related to
Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled AnalysisWolfgang Janni, Thomas W P Friedl, Tracy C Yab, et al.Breast Care (Basel, Switzerland)|April 2, 2020
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA StudiesMarina Elena Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.Journal of Experimental & Clinical Cancer Research : CR|December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER StudyGiulia Bon, Laura Pizzuti, Valentina Laquintana, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast CancerMarco Tagliamento, Alessandra Gennari, Matteo Lambertini, et al.Critical Reviews in Oncology/Hematology|February 18, 2019
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paperMassimo Cristofanilli, Jean-Yves Pierga, James Reuben, et al.Scientific Reports|July 3, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trialLaura Pizzuti, Maddalena Barba, Marco Mazzotta, et al.Cancer Treatment Reviews|October 22, 2024
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus projectStefania Gori, Fiorenza De Rose, Antonella Ferro, et al.Journal of the National Cancer Institute|April 17, 2018
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysisFrançois-Clément Bidard, Stefan Michiels, Sabine Riethdorf, et al.Journal for Immunotherapy of Cancer|March 23, 2021
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory ScoreGino M Dettorre, Saoirse Dolly, Angela Loizidou, et al.Journal of Cellular Physiology|January 17, 2020
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidenceEriseld Krasniqi, Laura Pizzuti, Giacomo Barchiesi, et al.Pageof 26